Alaunos Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-4.2M | $-4.7M | $-4.7M | $-37.7M | $-78.8M | $-80.0M | $-117.8M | $-53.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $7.0K | $2.0K | $2.3M | $2.8M | $2.6M | $1.1M | $629.0K | $575.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $796.0K | $435.0K | $2.8M | $3.5M | $10.8M | $6.8M | $6.3M | $7.5M |
| Net Cash from Operating Activities | $-2.9M | $-5.0M | $-30.1M | $-29.2M | $-61.5M | $-57.0M | $-40.9M | $-49.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $98.0K | $0 | $197.0K | $216.0K | $3.3M | $9.8M | $284.0K | $459.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-98.0K | $0 | $1.3M | $-193.0K | $-3.3M | $-9.8M | $-284.0K | $-459.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $0 | $45.0K | $0 | — | $653.0K | $1.6M |
| Net Cash from Financing Activities | $3.3M | $0 | $-18.1M | $6.4M | $25.8M | $102.1M | $59.2M | $40.3M |
| Net Change in Cash | $294.0K | $-5.0M | $-46.9M | $-23.1M | $-39.0M | $35.3M | $18.0M | $-9.6M |
| Free Cash Flow | $-3.0M | $-5.0M | $-30.3M | $-29.4M | $-64.8M | $-66.8M | $-41.1M | $-49.9M |